Marion Merrell Dow
This article was originally published in The Tan Sheet
Executive Summary
Licenses terfenadine carboxylate use patent from separations technology company Sepracor for $ 7.5 mil. In addition, MMD is acquiring a 5.9% equity stake in Marlborough, Mass.-based Sepracor for $ 10 mil. MMD has been developing a terfenadine carboxylate and holds a composition patent that is valid through 1998. The Seldane metabolite has been shown to be non-cardiotoxic. Reports of Seldane cardiovascular adverse events have badly damaged the product's potential for OTC marketing.